<DOC>
	<DOC>NCT00902564</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.</brief_summary>
	<brief_title>Escitalopram in Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description>The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characteristics (SPC).</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>The patient suffers from GAD, diagnosed according to ICD10 (International Classification of Diseases) The patient meets criteria as set out in the national SPC for escitalopram The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs The patient has/has had an alcohol or drug abuserelated disorder, as defined in ICD10 The patient has contraindications to escitalopram The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance The patient is pregnant or breastfeeding The patient, if a woman of childbearing potential, is not using adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>GAD</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Anxiolytic</keyword>
</DOC>